Please ensure Javascript is enabled for purposes of website accessibility

Bravo? Not Really.

By Brian Orelli, PhD - Updated Apr 6, 2017 at 8:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Teva's oral multiple sclerosis drug, laquinimod, fails to impress.

Teva Pharmaceuticals (Nasdaq: TEVA) released results for its Bravo clinical trial this morning, but the only ones clapping were Biogen Idec's (Nasdaq: BIIB) investors.

Bravo tested Teva's oral multiple sclerosis medication laquinimod with a placebo and Biogen's Avonex. The drug didn't reduce annualized relapse rate compared with placebo by a statistically significant margin, but Teva says the patients in the laquinimod and placebo groups had different MRI characteristics and therefore different prognoses. If you make a statistical correction for the differences in the treatment groups, laquinimod produced a 21% reduction in the annualized relapse rate. Teva claims the adjustment was pre-specified, so the regulatory authorities should accept it, but it certainly doesn't sound as good as meeting the end point without statistical gymnastics.

In the trial, Avonex reduced annualized relapse rates, but that's not why Biogen's investors are happy. The company is developing an oral multiple sclerosis medication of its own called BG-12. The drug demonstrated a 53% reduction in annualized relapse rates, besting laquinimod even after the adjustment.

Laquinimod also passed a previous clinical trial, so Teva plans to submit marketing application in the U.S. and EU. At this point, whether the Food and Drug Administration or other regulatory authorities accept the statistical adjustment doesn't really matter; laquinimod is going to have a hard time competing with BG-12 for a spot in doctors' medicine bags.

In the oral multiple sclerosis space, that leaves BG-12 competing with Novartis' (NYSE: NVS) Gilenya, which is already approved, and potentially Sanofi's (NYSE: SNY) teriflunomide, although the latter didn't have the superb data that BG-12 put up. They'll all have the advantage of being taken orally compared with the current treatments like Avonex, Bayer's Betaseron, and Rebif sold by Pfizer (NYSE: PFE) and Merck KGaA that have to be injected or infused.

This is a big loss for Teva. It still has its injected multiple sclerosis medication, Copaxone, but one has to think BG-12 will start whittling into those sales.

Keep track of all our Foolish analysis on Teva by adding it to the Fool's free My Watchlist service. Just click here to get started.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$7.89 (4.92%) $0.37
Sanofi Stock Quote
$51.01 (1.96%) $0.98
Pfizer Inc. Stock Quote
Pfizer Inc.
$52.31 (-0.23%) $0.12
Novartis AG Stock Quote
Novartis AG
$84.36 (-0.20%) $0.17
Biogen Inc. Stock Quote
Biogen Inc.
$210.63 (3.28%) $6.69

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.